Related Experiment Video
Updated: Jul 11, 2025
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
Gennaro Gadaleta-Caldarola1, Laura Lanotte1, Stefania Infusino2
1Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli" Asl BT, Viale Ippocrate, 15, 70051 Barletta (BT), Italy.
Background:
TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd).
Research Design And Methods:
Herein, we performed a meta-analysis aimed to evaluate any grade adverse events, grade 3-4 adverse events, dose reduction, and serious adverse events in TNBC patients treated with Dato-DXd in clinical trials.
Results:
The pooled results suggests that Dato-DXd is associated with a favorable safety profile: while any grade treatment-related toxicities were common, grade 3-4 events were not particularly frequent and mainly represented by stomatitis (13.88%; 95% CI, 10.68 - 17.09).
Conclusions:
These findings may help to comprehensively define the safety profile of Dato-DXd and to assist in the design of future clinical trials in this setting.
Insights
Datopotamab deruxtecan (Dato-DXd) shows a favorable safety profile for triple-negative breast cancer (TNBC) patients. While mild side effects were common, severe events were infrequent, primarily stomatitis.
Area of Science:
- Oncology
- Pharmacology
Background:
- Trop-2 targeted therapy is a promising strategy for triple-negative breast cancer (TNBC).
- Datopotamab deruxtecan (Dato-DXd) is an investigational agent targeting Trop-2.
Approach:
- A meta-analysis was conducted on clinical trial data.
- Evaluated adverse events (any grade, grade 3-4, serious), and dose reductions for Dato-DXd in TNBC patients.
Key Points:
- Dato-DXd demonstrates a favorable safety profile in TNBC.
- Any grade treatment-related toxicities were common.
- Grade 3-4 adverse events were infrequent, with stomatitis being the most common (13.88%).
Conclusions:
- Findings help define the safety profile of Dato-DXd.
- Results can inform future clinical trial designs for TNBC treatment.
More Related Videos
09:29Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017